Swiss born, Sekuana Medical has developed a pump that can be implanted into the body for the treatment of liver-associated diseases.
Sekuana Medical, a medical devices company that is active in developing a variety of diseases solutions, announced this morning its intention to launch IPO at Euronekt Brussels.
If the transaction materializes, it will join biotechnology section already well developed in our market, and especially the "MedTechs" sub-segment that already includes Curetis
. These two companies have developed mini-laboratories for the diagnosis of certain diseases from different cartridges. IBA
can also fall into this category.
Swiss origin, or installed in GhentSekuana Medical is already in the commercial phase in seven European countries. She developed a pump, alfapump who received the CE mark for refractory liver ascites and malignant ascites. Ascites is abnormal fluid accumulation in the abdomen.
With this implanted pump, the system collects ascites and transports them to the bladder, where it is naturally eliminated through urine. The pump can be installed in less than an hour under local or general anesthesia, explains Sekuana, who reports 650 locations already finished. From April 2018, alfapump is included in the guidelines of the European Association for the study of both decompensated cirrhosis.
In the United States alone, 3.9 million adults lived chronic liver disease. In recent years, NASH, a serious liver disease associated with obesity, has experienced significant growth, especially in the United States.
In addition, "MedTech" has also developed therapy, "direct sodium suppression", DSR "for the treatment of volume overload in cardiac insufficiency. He plans to start his first human studies by the end of this year. "About 6.5 million adults in the United States suffer from such deficiencies and it is expected that this figure will increase to 8 million" says the company.
Ablink student on the board
At this stage, Sekuana does not provide details about the amount to which the raise is expected, nor the number of shares offered, their price, the calendar … According to consumers, Ian Crosbie, executive director of biotechnology What will the funds be used for?. "The IPO will provide funding for a key study in the United States for alfapump for liver ascites, for commercial deployment in Europe, first human studies for DSR therapy and for other clinical programs in Europe. "
After closing the IPO, organized by KBC Securities, Kempen & Co and Mirabaud, Sekuana Medical intendsexpand your board of directors. Pierre Chauvineau he will be appointed president and Vim Ottevaere he will be a non-executive director. The other was Ablink's chief financial officer at the time Sanofi took over 3.9 billion euros.